Walleye Capital’s Bone Biologics BBLG Stock Holding History

Walleye Capital’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,629	Closed	-$192K	–	4935
2023 Q3	$192K	Sell	5,629 -517	-8%	-$25.6K	﹤0.01%	3580
2023 Q2	$419K	Buy	6,146 +5,586	+998%	+$1.46M	﹤0.01%	2561
2023 Q1	$208K	Sell	560 -17	-3%	-$7.09K	﹤0.01%	2440
2022 Q4	$170K	Buy	+577	New	+$325K	﹤0.01%	2140

Other funds holding BBLG

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Walleye Capital's BBLG Position: Q4 2023 in Review

Walleye Capital sold out of Bone Biologics (BBLG) in Q4 2023, closing a stake of 5,629 shares — an estimated $192K sold.

Walleye Capital first reported a position in BBLG in Q4 2022 and held it in 4 quarters. The position peaked at $419K in Q2 2023. 2 funds tracked by Wall St. Rank hold BBLG as of Q4 2023.

Walleye Capital reported no remaining Bone Biologics position as of Q4 2023 after selling out during the quarter.
Walleye Capital sold 5,629 Bone Biologics shares in Q4 2023, an estimated $192K.
Walleye Capital first reported a position in Bone Biologics in Q4 2022 and held it in 4 quarters.
Walleye Capital's Bone Biologics position peaked at $419K in Q2 2023.
2 funds tracked by Wall St. Rank held Bone Biologics as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.